ERBB2 and cancer: Furthermore, another report demonstrated that conditioned medium from cancer-reprogrammed fibroblasts more effectively limits the therapeutic efficacy of HER2 kinase blockade compared to conditioned medium from tumor-naïve fibroblasts [41].